Antisense Oligonucleotides Targeting CTGF to Reduce Hypertrophic Scarring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dermal scarring, such as hypertrophic scars, lack specificity and efficacy, with no FDA-approved drugs available, and existing approaches to modulate Transforming Growth Factor-Beta (TGF-β) often hinder wound healing.
Innovation Solution
Administration of antisense oligonucleotides that inhibit Connective Tissue Growth Factor (CTGF) expression to reduce hypertrophic scarring, targeting specific pathways involved in scarring without affecting wound closure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If TGF-β is targeted to reduce fibrosis, then scarring is reduced, but wound healing is delayed
Solution Approach 1:
The patent segments the TGF-β pathway by targeting CTGF (connective tissue growth factor) specifically rather than TGF-β itself. CTGF is a downstream effector that mediates fibrotic effects, so inhibiting it reduces scarring while preserving the beneficial wound healing functions of TGF-β. This segmentation allows selective modulation of the fibrotic arm of the pathway without blocking the healing arm.
Solution Approach 2:
The patent uses CTGF as an intermediary target between TGF-β and fibrosis. By blocking CTGF expression (using antisense oligonucleotides), the patent interrupts the path from TGF-β signaling to fibrotic outcomes. This intermediary approach allows TGF-β to continue performing its pro-healing functions while preventing excessive fibrosis through CTGF inhibition.
2Ease of manufacture
If non-specific treatment modalities are used, then treatment simplicity is maintained, but efficacy is limited
Solution Approach 1:
The patent changes the molecular parameter of specificity by using antisense oligonucleotides that are sequence-specific for CTGF. This molecular-level specificity transforms the treatment from non-specific to highly specific, enabling precise modulation of CTGF expression. The antisense compounds bind to CTGF mRNA and prevent translation, achieving both simplicity in administration and high efficacy through targeted molecular action.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively reduces hypertrophic scarring severity without impairing wound healing, as demonstrated by reduced CTGF mRNA and protein levels and scar elevation indices in rabbit models, with late administration showing better efficacy.
Implementation Method 1
Administration of antisense oligonucleotides that inhibit Connective Tissue Growth Factor (CTGF) expression
Data Source
Figure 1
Figure 2A~2D
Figure 3
AI summary
This invention provides a method for reducing hypertropic scarring resulting from dermal wound healing in a subject in need which comprises administering to the subject an antisense oligonucleotide which inhibits expression of connective tissue growth factor (CTGF) in an amount effective to inhibit expression of CTGF and thereby reduce hypertrophic scarring.